ArticleInternational journal of molecular sciences2026
Combined SGLT-2 Inhibitor and Mineralocorticoid Receptor Antagonist Therapy: Effects on the Renin-Angiotensin-Aldosterone System in Heart Failure Treatment.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2is), originally developed as glucose-lowering agents for type 2 diabetes mellitus, have increasingly demonstrated clinical benefits in patients with chronic kidney disease and heart failure. We retrospectively evaluated 114 patients with heart failure admitted to the Emergency Medicine Unit of Policlinico Umberto I, Sapienza University of Rome, Italy, between March and December 2025. Patients were stratified into three groups: initiation of combined SGLT2i and mineralocorticoid receptor antagonist (MRA) therapy (Group A), initiation of SGLT2i alone (Group B), or ongoing SGLT2i therapy for >12 months (Group C). Hemodynamic parameters, serum and 24 h urinary electrolytes, and hormonal parameters were assessed at admission (T0), 7 days (T1), and 30 days (T2). Baseline anthropometric and laboratory parameters were comparable among groups, except for baseline 24 h urinary glucose excretion, significantly increased in Group C compared to Groups A-B. Hypertension was the most prevalent comorbidity (74%), followed by atrial fibrillation (49%), dyslipidemia (47%), and coronary artery disease (39%). Groups A and B showed activation of the renin-angiotensin-aldosterone system, while Group A exhibited increased 24 h urinary sodium and chloride excretion and lower urinary albumin excretion. These findings confirm that SGLT2i therapy, particularly when combined with MRAs, may favorably influence natriuresis, chloruresis, and urinary albumin excretion in patients with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.